Interstitial lung diseases (ILDs) are defined as diffuse parenchymal pathologies that begin in the lung interstitium.\[[@ref1]\] The American Thoracic Society (ATS)/European Respiratory Society (ERS) International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias gives a clear approach to idiopathic interstitial pneumonias.\[[@ref1]\] Idiopathic pulmonary fibrosis (IPF) is a major subtype, defined as "a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, limited to the lungs, and is associated with the histopathologic and/or radiologic pattern of usual interstitial pneumonia."\[[@ref2]\] IPF is rare and usually idiopathic, and has a poor predictable clinical course with a high mortality rate. It is also challenging to diagnose, requiring extensive workup. Clinical and demographic data on IPF are limited yet show substantial differences in different world regions.\[[@ref3]\] Worldwide, the prevalence estimates for IPF range from 6 to 32 per 100,000. One review found that the males with IPF were more likely to be in their 60s.\[[@ref4]\] A study from Saudi Arabia included 330 patients with ILD, out of which 23% had IPF.\[[@ref5]\]

The age of presentation is typically 50-70 years, and symptom onset is typically 2-4 years prior to presentation.\[[@ref6]\] Nalysnyk *et al*.,\[[@ref7]\] estimated that in the United Kingdom there are approximately 15,000 IPF patients, with approximately 5000 new IPF patients being diagnosed each year, while Navaratnum *et al*.,\[[@ref8]\] believe the incidence is on the rise. Raghu *et al*.,\[[@ref9]\] estimated that in the United States, there are 132,000-200,000 IPF patients with an annual incidence of 50,000. The usual presenting symptoms are dry cough and moderate to severe dyspnea on exertion. However, comprehensive data is lacking from Saudi Arabia and the Middle East.\[[@ref5]\]

In the absence of a diagnostic biopsy, typical clinical findings (described below) would suggest the diagnosis of IPF.\[[@ref10]\] The differential diagnoses include other idiopathic interstitial pneumonias, connective tissue diseases (systemic sclerosis, polymyositis, and rheumatoid arthritis), chronic hypersensitivity pneumonitis, and environmental and/or occupational exposures.

High-resolution computed tomography (HRCT) is essential in diagnosing IPF and has become more widely available. The 2011 ATS guidelines for diagnosing IPF require HRCT for patients in whom surgical lung biopsy is contraindicated. HRCT features add prognostic information to the histologic diagnosis of usual interstitial pneumonia. A significantly increased mortality rate was observed in patients who displayed both HRCT and histologic criteria (i.e., radiographic honeycombing).\[[@ref11]\]

Following the diagnosis of IPF in the United States, the median survival period was found to be 2-5 years.\[[@ref2][@ref12]\] However, Esam *et al*. found the median survival period to be 7.6 years in Saudi Arabia, contrasting 3.4-5.8 years in other studies.\[[@ref13]\] Associated comorbidities such as gastroesophageal reflux disease (GERD) and ischemic heart disease confound the progression of IPF.\[[@ref14]\] Maintained lung physiology correlated to improved survival in some studies.\[[@ref15]\] Anti-inflammatory, anti-fibrotic, and immunosuppressive therapies are often used to treat IPF, though have not been proven to improve neither survival nor quality of life.\[[@ref16]\]

We retrospectively studied data from IPF patients in Saudi Arabia, in particular the frequency, characteristics, and cofactors of IPF in Saudi Arabia, in order to compare our findings to other regions. Data in this regard are very limited, and the only few available studies about ILD only report a small cohort of patients with IPF. Therefore, IPF patients were the main focus of this study.

Methods {#sec1-1}
=======

This retrospective study was approved by the institutional review boards of study institutions, which deemed informed consent unnecessary because the study was retrospective and no patient-identifying data would be disclosed.

Patient data from King Faisal Specialist Hospital and Research Center-Jeddah and King Abdulaziz University Hospital-Jeddah during the period 2007 to 2012 were used. All patients presenting to the out-patient pulmonary clinics and in-patient services were screened, out of which, patients with diagnosis codes for interstitial lung disease, idiopathic lung fibrosis, lung fibrosis, and diffuse parenchymal lung disease, were included. Additional IPF cases were identified from the radiology department database by selecting those with computed tomography-requiring diagnoses.

IPF symptoms, along with laboratorial, radiologic, and pathological signs, as well as pulmonary function tests, were also considered. The diagnosis of IPF was established when the patient met the following criteria, according to the ATS/ERS recommendations:\[[@ref10]\]

Exclusion of other known causes of ILD by complete history, mainly other symptoms that could suggest autoimmune disease, drugs, or occupational or exposure historyPulmonary function test results showed restrictive and/or gas-transfer defectsUnexplained dyspnea on exertionIllness duration ≥3 monthsBilateral basal inspiratory cracklesTypical HRCT findings: Predominantly basal/sub-pleural coarse reticular or linear opacities, honeycombing, and traction bronchiectasis, but no ground-glass opacitiesNegative laboratory serology for autoimmune diseases

Data on demographics, physical examination findings, laboratory, chest X-rays, HRCTs, electrocardiograms, echocardiograms, pulmonary function test results, pathological and bronchoalveolar lavage findings, functional illness severity assessments, and comorbidities was collected. Furthermore, data was collected on drugs administered and disease course (including hospital admissions, and outcomes). Exclusion criteria included a previously established diagnosis of a connective-tissue disease, occupational and/or environmental exposure to a substance that could potentially cause ILD, and a history of ingesting drugs and other agents that are known to cause pulmonary fibrosis.

Statistical analysis {#sec2-1}
--------------------

Missing values were assumed to represent the worst-case scenario. One-way analysis of variance and the Monte Carlo test were suitably applied to analyze the overall variables. Qualitative and categorical variables were compared using the Kruskal-Wallis test and the chi-square test. Quantitative continuous variables were analyzed with the chi-square test. All analyses were carried out on an intention-to-treat basis.

Results {#sec1-2}
=======

There were 176 patients with interstitial lung diseases, of whom 134 were diagnosed with IPF. The patients were predominantly female and were overweight with average body mass index 29 ± 8 kg/m^2^. More than half were already on home oxygen at presentation \[[Table 1](#T1){ref-type="table"}\].

###### 

Patients baseline demographics

![](ATM-9-168-g001)

Patients' signs and symptoms at presentation are illustrated in detail in [Table 2](#T2){ref-type="table"}.

###### 

Co-morbidities, signs and symptoms in patients at initial presentation

![](ATM-9-168-g002)

They had moderate reduction in FEV1 and FVC, showed restrictive pattern on spirometry and had moderate reduction in the diffusing capacity of the lung for carbon monoxide. They also had mild pulmonary hypertension via echocardiography \[[Table 3](#T3){ref-type="table"}\].

###### 

Respiratory and cardiac testing at baseline
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The findings on Computed Tomographic scans and treatments received are outlined in [Table 4](#T4){ref-type="table"}.

###### 

Laboratory and radiographic findings along with therapies used

![](ATM-9-168-g004)

The IPF patients' frequency of hospital admission (*n* = 99) was 2.4 ± 1.7 per year, and hospital stay (*n* = 99) was 17.4 ± 23.8 days. Overall 1 year survival in all IPF patients was good, 93% (124) patients remained alive after 1 year \[[Table 5](#T5){ref-type="table"}\].

###### 

Hospital admission data along with survival
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Discussion {#sec1-3}
==========

This is the largest reported IPF cohort pertaining to Saudi Arabia to date. The mean age of presentation in our study of 64 ± 13 years is similar to other studies.\[[@ref6]\] Similarly, our study population\'s mean BMI (29 ± 8 kg/m^2^) was in line with prior reports which show that a higher BMI is associated with a better prognosis.\[[@ref17]\] Only 32 percent of our cohort had finger clubbing.

Diabetes, common in our patients, is suspected to increase the risk of IPF.\[[@ref18][@ref19]\] Ischemic heart disease and GERD were also more common in our cohort than in the general population, as has been found in other studies.\[[@ref20][@ref21]\] Use of GERD medications is an independent predictor of longer survival in patients with IPF. That finding supports the hypothesis that GERD and chronic micro-aspiration increase the risk of IPF.\[[@ref22][@ref23][@ref24]\]

Twelve percent of our IPF patients had pulmonary hypertension, the presence of which is another predictor of survival.\[[@ref25]\] Fifty-three percent of our IPF patients were on home oxygen at presentation, which probably indicates delayed diagnosis and referral to our hospital.\[[@ref26]\] Baseline pulmonary function test results can predict the risk of hospitalization. Martinez *et al*. reported that patients with a median percent-of-predicted FVC of ≤62% were more likely to be hospitalized (42% *vs*. 26%) and the similar trend was found in our cohort. Further study is also needed on the relationships between hospitalization risk and pulmonary-function-test and 6-min-walk-test results in IPF patients.\[[@ref27][@ref28][@ref29]\]

This study showed that 88/134 (66%) of IPF patients had slowly progressive IPF.\[[@ref12]\] This may have contributed to the relatively long mean survival. There was a similitude of findings between Esam *et al*.,\[[@ref13]\] and this study in terms of comparable survival rates among patients from different regions of Saudi Arabia. More studies are needed on the subject of IPF among different ethnicities among the Saudi population.\[[@ref30]\]

There were two limitations in our study. First, as this was a retrospective study, it was not possible to collect data that might have been valuable, such as thorough occupational and environmental exposures, baseline FVC, total lung capacity, and DLCO. Second, there was a chance of selection bias due to the fact that tertiary care centers were used and, also, because of the free availability of HRCT thus facilitating earlier detection of IPF as compared to some of the other regions.

Conclusions {#sec1-4}
===========

IPF patients in Saudi Arabia are most often elderly, obese, and female. Thirty-six percent of our cohort was smokers, and other types of air pollution (e.g., wood smoke and engine exhaust) might be risk factors for IPF. Compared to cohorts in other studies, our patients had similar symptoms but were a little older at presentation, and disease progression appeared to be slower. Genetic factors probably play a role in IPF risk and progression. Geographic variability of IPF prevalence may be influenced by differences in mortality, possibly as a result of the influence of comorbidities such as diabetes, GERD, pulmonary hypertension, and ischemic heart disease. Therefore, epidemiologic estimates from other studies cannot be directly compared without accounting for this heterogeneity. Future studies should be prospective and collect more detailed information.

Our results are clinically relevant because they may improve early diagnosis. Given the current absence of medical therapies to improve survival, this enhanced understanding of the natural history of IPF strongly encourages more frequent patient reevaluation, research on new approaches to recognizing and managing IPF, and early referral for lung transplantation.
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